pembrolizumab
Interviews and expert commentary tagged “pembrolizumab” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
ESMO 2025; Christof Vulsteke MD PhD: Perioperative Enfortumab Vedotin Therapy With Pembrolizumab Boosts Event-Free and Overall Survival in Platinum-Ineligible Patients with Muscle-Invasive Bladder Cancer: KEYNOTE-905 study
A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905 study of perioperative antibody drug conjugate thereapy with
Domenica Lorusso MD PhD: Adding Early PD-1 Checkpoint Inhibition brings Big Reduction of Deaths for Patients with Newly Diagnosed Locally Advanced High-Risk Cervix Cancer
Domenica Lorusso MD PhD: Initial therapy with Pembrolizumab added to chemoradiotherapy boosts survival in high-risk locally advanced cervix cancer
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the
First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer
Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to ini
Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit
COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n